Alaunos Therapeutics, Inc.

Alaunos Therapeutics, Inc. is a clinical-stage oncology-focused cell therapy company specializing in adoptive TCR engineered T-cell therapies. The company's TCR Library, currently in Phase I/II clinical trials, targets ten TCRs reactive to mutated KRAS, TP53, and EGFR for the treatment of various cancers. Additionally, Alaunos Therapeutics, Inc. develops hunTR, a human neoantigen T-cell receptor platform, and mbIL-15 for solid tumor treatment. The company generates revenue through its licensing agreements with PGEN Therapeutics, Inc., research and development collaboration with The University of Texas MD Anderson Cancer Center, and patent license agreement and research and development collaboration with the National Cancer Institute.

Products

• Adoptive TCR engineered T-cell therapies

• hunTR human neoantigen T-cell receptor platform

• mbIL-15 for solid tumor treatment